Evidence map›Paper›PMID 39706803›Full record

Trial reportPsycho-oncology2024

Intervention-Related Changes in Coping Ability Drives Improvements in Mood and Quality of Life for Patients Taking Adjuvant Endocrine Therapy.

Leah E Walsh, Laura Dunderdale, Nora Horick, Jennifer S Temel, Joseph A Greer, Jamie M Jacobs

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Psycho-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03837496 (Symptom-Targeted Randomized Intervention for Distress and Adherence to Adjuvant Endocrine Therapy), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03837496 nacompletednot on this map

Symptom-Targeted Randomized Intervention for Distress and Adherence to Adjuvant Endocrine Therapy (STRIDE) Among Breast Cancer Survivors: A Pilot Feasibility Trial

TypeinterventionalSponsorMassachusetts General HospitalRan2019 to 2021Enrolled100ConditionsBreast Cancer, Adherence, MedicationArmsSTRIDE, Medication Monitoring Control
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Coping Strategies and Health-Related Quality of Life in Breast Cancer Survivors.European journal of investigation in health, psychology and education · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Leah E WalshIcahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0001-7081-0306
Laura DunderdaleMassachusetts General Hospital, Boston, Massachusetts, USA.
Nora HorickMassachusetts General Hospital, Boston, Massachusetts, USA.
Jennifer S TemelMassachusetts General Hospital, Boston, Massachusetts, USA.
Joseph A GreerMassachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-0979-4076
Jamie M JacobsMassachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-9740-624X

Funding

Training Program in Cancer Prevention and Control for Priority PopulationsT32CA225617 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Guy H Montgomery, JUAN P WISNIVESKY · 2018 to 2026
$2.6M
Improving Adherence to Endocrine Therapy in Breast Cancer SurvivorsK07CA211107 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JACOBS, JAMIE MICHELE · 2017 to 2021
$875k
K07CA211107NCI NIH HHS K07 CA211107NCI NIH HHS T32 CA225617NIH HHST32CA225617
6 · The paper itself

Abstract

objectiveA recent randomized trial of a group psychosocial telehealth intervention (STRIDE) improved anxiety, depression, quality of life (QOL), symptom distress, coping, and self-efficacy to manage symptoms related to taking adjuvant endocrine therapy (AET) in women with non-metastatic hormone receptor-positive breast cancer. This study examined whether changes in coping and self-efficacy mediated intervention effects on anxiety, depression, QOL, and symptom distress.

methodWomen (N = 100) were recruited between 10/2019-06/2021 from Massachusetts General Hospital and were randomized to STRIDE or to the medication monitoring control group. Participants completed self-report measures of anxiety and depression (Hospital Anxiety and Depression Scale), QOL (Functional Assessment of Cancer Therapy-Breast Cancer scale), symptom distress (Breast Cancer Prevention Trial Symptom Scale), coping (Measure of Current Status-Part A), and self-efficacy (Self Efficacy for Managing AET Symptoms) at baseline and 24-week follow-up. Mediated regression models tested whether changes in coping ability and self-efficacy mediated the intervention effects on anxiety, depression, QOL, and symptom distress, controlling for key variables.

resultsImprovements in coping across the 24-week study period mediated the effect of STRIDE on anxiety symptoms (indirect effect, B = -0.61, SE = 0.28, 95% CI: -1.28, -0.17), depressive symptoms (indirect effect, B = -0.50, SE = 0.21, 95% CI: -0.97, -0.15), and QOL (indirect effect, B = 3.80, SE = 1.25, 95% CI: 1.54, 6.49), but not symptom distress. Changes in self-efficacy did not mediate improvements in any of the proposed outcomes.

conclusionCoping is an essential component of a brief group psychosocial intervention that drives improvements in mood and QOL for women with non-metastatic hormone receptor-positive breast cancer taking AET. CLINICAL

trial registrationNCT03837496.

Indexed as

Adaptation, PsychologicalAntineoplastic Agents, HormonalAnxietyBreast NeoplasmsDepressionQuality of LifeSelf EfficacyAdultAffectAgedChemotherapy, AdjuvantFemaleHumansMiddle AgedAntineoplastic Agents, Hormonaladjuvant endocrine therapybreast cancercancercoping skillsmediationmoodoncologyquality of lifeself‐efficacy

Identifiers

PMID39706803
PMCPMC11936010

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.